

Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Biocure Technology Inc. (the “Company”)
950-1130 West Pender Street
Vancouver, B.C. V6E 4A4

Item 2 Date of Material Change

June 30, 2024

Item 3 News Release

A news release was disseminated on July 3, 2024 through the facilities of Stockwatch.

Item 4 Summary of Material Change

The Company’s letter agreement dated September 14, 2023 (the “Letter Agreement”) with Atriva Therapeutics GmbH (“Atriva”) whereby the Company would acquire all of the issued and outstanding securities of Atriva (the “Transaction”) has been terminated.

Item 5 Full Description of Material Change

The Letter Agreement has been mutually terminated due to passage of time without completion of the Transaction.

There was no penalty or termination fee payable by either the Company or Atriva in connection with the termination of the Agreement. Trading in the common shares of the Company was halted on September 18, 2023, upon announcement of the Transaction in accordance with the policies of the Canadian Stock Exchange (“CSE”).

Following the termination of the Transaction, the CSE has determined that the Company has not met continued listing requirements and has been deemed to be inactive and a X. extension evidencing same is added to the listed securities of the Company.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

Item 7 Omitted Information

No information has been omitted on the basis that it is confidential information.

Item 8**Executive Officer**

Konstantin Lichtenwald is knowledgeable about the material change and the Report and may be contacted (604) 609-7146.

Item 9**Date of Report**

July 5, 2024